Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study.

Journal:

Journal of Clinical Oncology

Published:

2026-01-16

DOI:

10.1200/jco-25-00826

Affiliations:

9

Authors:

13

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	7.000000	0.54
Institute Gustave-Roussy (IGR), France	1.000000	0.08
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.08
Istinye University (ISU), Turkey	1.000000	0.08
START-Madrid-FJD, Spain	1.000000	0.08
Chonnam National University, South Korea	1.000000	0.08
Queen Mary University of London (QMUL), United Kingdom (UK)	0.500000	0.04
St Bartholomew's Hospital, United Kingdom (UK)	0.500000	0.04

Interested in Oncology and Carcinogenesis?